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Imatinib (Gleevec) is the effective therapy for BCR-ABL positive CML patients. Point mutations have been detected in ATP-binding 
domain of ABL gene which disturbs the binding of Gleevec to this target leading to resistance. Detection of mutations is helpful in 
clinical management of imatinib resistance. We established a very sensitive (ASO) PCR to detect mutations in an imatinib-resistant CML 
patient. Mutations C944T and T1052C were detected which cause complete partial imatinib resistance, respectively. This is the first 
report of multiple point mutations conferring primary imatinib resistance in same patient at the same time. Understanding the biological 
reasons of primary imatinib resistance is one of the emerging issues of pharmacogenomics and will be helpful in understanding primary 
resistance of molecularly-targeted cancer therapies. It will also be of great utilization in clinical management of imatinib resistance. 





Chronic myeloid leukemia (CML) is a stem cell disorder (1). This 
is a myeloproliferative disease characterized by marked increase 
in granulocytes, marked bone marrow hyperplasia and 
spleenomegaly (2). The symptoms which appear in initial phase 
are non-specific including fever, anaemia, fatigue, weight loss, 
weakness, and others (3). CML primarily affects the adults 
between 25-60 years of age and accounts for 15-20% of all 
leukemia cases (4). 
 
CML is associated with presence of Philadelphia (Ph) 
chromosome detectable microscopically which results from 
balanced chromosomal translocation t (9:22) (q34; q11), that is, 
translocation of proto-oncogene ABL from chromosome 9 to 
BCR gene at Chromosome 22 (5). BCR-ABL translocation is 
common in 95% of patients and Ph chromosome is found in all 
dividing multipotent stem cells (5). BCR-ABL fusion gene 
formed as a result of this translocation encodes a protein which 
has tyrosine kinase and oncogenic activity (6). 
 
Median survival for CML patients is 3-8 years after clinical 
manifestation of the disease and physicians have very little time 
for treatment of this fatal disease (7). Hydroxyurea and interferon 
are first-line treatment for CML patients but usually patients 
show resistant to these therapies (8). STI 571 commonly called as 
Imatinib or Gleevec is currently the most specific drug for CML 
patients and is regarded as very effective therapy for CML Iqbal et al.    
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patients (9). This drug binds to ATP -binding site of tyrosine 
kinase domain in bcr-abl  protein, a protein which triggers the 
carcinogenesis pathway leading to manifestation of the disease 
(10). Thus, by occupying and blocking the ATP binding site, it 
stops the signal transduction leading to onset of Leukemia (10). 
However, a considerable number of patients have been reported 
to show resistance to Gleevec, leading to relapses (11). Resistance 
against Gleevec has been attributed to mutations in the ATP–
binding site of tyrosine-protein kinase domain of the BCR-ABL 
gene which lead to conformational changes in bcr-abl  protein 
resulting in impairment of Gleevec binding (11-14). Many BCR-
ABL single base pair mutations have been found in Gleevec 
resistant CML patients (15). It has been reported that different 
mutations in tyrosine-protein kinase domain of the BCR-ABL 
transcript lead to different degree of the drug resistance, 
depending upon the nature and location of the mutations (16). 
Some of the mutations lead to moderate resistance and dose 
escalation can efficiently overcome Gleevec resistance in these 
cases (17). On the other hand, some of the mutations lead to 
complete drug resistance (16-18). Under such circumstances, 
combination therapies with Gleevec or use of some substitution 
therapy have been reported to manage this resistance (19, 20). 
 
We checked mutations in ABL gene ATP-binding domain of a 
CML patient who had been on oral dose of 400mg/day of 
Gleevec for nine months. Patient had no hematological, 
cytogenetic or molecular response to Gleevec. A very sensitive 
ASO-PCR method (21) was used to detect three mutations 
namely C944T, T932C and T1052C. Interestingly, we found two 
mutations in this patient: C944T mutation causing threonine to 
isoleucine substitution at amino acid 311 and T1052C mutation 
leading to amino acid substitution from methionine to leucine at 
position 351. This is the first report of double mutation in ABL 
gene ATP-binding domain of a Gleevec resistance CML patient. 
This new finding and its biological and clinical implications are 
discussed. 
 
METHODS AND MATERIALS 
 
Patient’s inclusion criteria: A CML patient with oral dose of 400 
mg/day for nine months of Gleevec who has no hematological, 
cytogenetic and molecular response to drug was investigated for 
ABL gene ATP-binding domain mutations responsible for 
Gleevec resistance. Blood sample was taken from patient in 
EDTA. Consent from patient was obtained for this study. 
 
DNA Extraction: Genomic DNA was extracted from patient’s 
blood using the method described by Sambrook et al. in 1989 (22) 
with little modifications and optimization. Briefly: 
 
1.  One ml of blood was taken. It was mixed with 9 ml of 
Buffer A (Sucrose 10.95g, 1M Tris HCl 1ml, 1M MgCl2 500 
µl and 1 ml of Triton per 100 ml of buffer ), incubated on 
ice for 2 minutes and spun at 1500 rpm for 15 minutes at 
4°C. 
2.  Pink pellet of nuclei was resuspended in 320 µl of cold 
Buffer B (25 ml of EDTA pH 8, 20 ml of 5M NaCl per 100 
ml of buffer). Thirty two µl of 10% SDS and 3.5 µl of 
Proteinase-K (10mg/ml) were added. The mixture was 
subjected to shaking incubation at 37°C overnight. 
3.  An equal volume of buffer-equilibrated phenol was added 
and mixed on ice for 10-15 minutes. It was centrifuged at 
2500 rpm for 15 minutes at 4°C. 
4.  Supernatant was taken, an equal volume of chloroform: 
isoamyl alcohol (24:1) was added and mixed gently at room 
temperature for 15-30 minutes. Phases were separated by 
centrifugation at 2500 rpm for 15 minutes at 4°C. 
5.  Supernatant was taken, 1/10 volume of 3M sodium acetate 
and 1.5 volume of 100% isopropanol was added. DNA was 
precipitated. 
6.  Pellet was obtained by centrifugation at 14,000 rpm for 20-
30 minutes at room temperature. It was washed with 70% 
ethanol and air-dried. 
7.  Pellet was dissolved in Tris EDTA buffer, DNA quantity 
estimated spectrophotometrically and stored at -20°C. 
 
Allele-specific oligonucleotide (ASO) PCR: Allele Specific 
Oligonucleotides (ASO) and Normal Primers (NP): ASO-PCR 
assay described by Catherine Roche-Lestienne et al. (2002) (21) 
was used for detection of three mutations of ABL gene ATP-
binding domain namely C944T, T932C and T1052C. DNA was 
amplified with normal primer (NP) or mutation specific forward 
primers (ASO) and a common reverse primer. The identitities 
and sequences of the primers are given in Table 1. 
 
Table 1: Identities and sequences of Primers used in ASO-PCR (Difference 











A1 NP  Forward 
GCC CCC GTT CTA 
TAT CAT CAC 
A2 ASO  Forward 
GCC CCC GTT CTA 
TAT CAT CAT  1 C944T 
R1 Common  Reverse 
GGA TGA AGT TTT 
TCT TCT CCA 
B1 NP  Forward 
CAC CCG GGA GCC 
CCC GT 
B2 ASO  Forward 
CAC CCG GGA GCC 
CCC GC  2 T932C 
R4 Common  Reverse 
CCC CTA CCT GTG 
GAT GAA GT 
C1 NP  Forward 
CCA CTC AGA TCT 
CGT CAG CCA T 
C2 ASO  Forward 
CCA CTC AGA TCT 
CGT CAG CCA C  3 T1052C 
R5 Common  Reverse 
GCC CTG AGA CCT 
CCT AGG CT 
 
PCR Mix preparation:  A 50 µl PCR reaction was performed 
containing 3µl of DNA, 10X PCR buffer (Fermentas, USA), 1.5 
mM MgCl2, 300 M each of dATP, dGTP, dCTP and dTTP, 1.5 
U Taq DNA polymerase (Fermentas, USA) and 25 pM each of 
forward and reverse primers. A negative control and a control 
from a clinically-declared healthy person with no Philadelphia 
positive leukemia were also included in the study. 
 
PCR Thermal Profile: Thermo cycling conditions for this ASO-
PCR conditions were 12 minutes at 94°C followed by 35 cycles of 
denaturation at 95°C for 1 minute, annealing at 64°C (for 
mutation 1 and 2) or 68°C (for mutation 3) for 1 minute and 
extension at 72°C for 1 minute, followed by a final extension at 
72°C for 5 minutes. 
 
Gel Electrophoresis: Amplified products from ASO-PCR were 
electrophorised at 1.5% gel and visualized and analysed after Iqbal et al.    
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Analysis of Mutation C944T 
 
Cytosine to Thymine mutation at position 944 of ABL gene was 
checked by ASO-PCR. Patient DNA and DNA from a healthy 
control were amplified with Allele-specific oligonucleotide as well 
as normal primer to give a PCR product of 158 bp. Although 
both patient and healthy control DNA yielded specific bands 
with normal forward primer, PCR product was observed only for 
patient when amplified using mutation specific primer (Fig 1). So, 
mutation C944T was found in this patient. 
 
Fig. 1: Detection of Mutation C944T Mutation by ASO-PCR. Lane 1: 
Negative control, Lane 2: Patient’s DNA amplified with normal primer, Lane 3: 
Patient’s DNA amplified with mutation specific primer (ASO), Lane 4: Control 
DNA amplified with normal primer, Lane 5: Control DNA amplified with 
mutation specific primer (ASO), Lane 6: DNA ladder (50 bp) Fermentas. 
 
Analysis of Mutation T932C 
 
Thymine to cytosine substitution at position 932 of ABL gene of 
Gleevec-resistance CML patient was checked by ASO-PCR. 
Patient DNA and DNA from a healthy control were amplified 
with allele-specific oligonucleotide (mutation specific primer) as 
well as normal primer to give a PCR product of 174 bp (Fig. 2). 
Specific band using normal primer was detected on gel for 
patient as well as healthy control but no PCR product was 
observed for patient DNA when amplified with mutation specific 
primer (ASO). 
 
Fig. 2: Detection of Mutation T932C Mutation by ASO-PCR. Lane 1: 
Negative control, Lane 2: DNA ladder (100 bp) Fermentas, Lane 3: Control 
DNA amplified with normal primer, Lane 4: Control DNA amplified with 
mutation specific primer (ASO), Lane 5: Patient’s DNA amplified with normal 
primer, Lane 6: Patient’s DNA amplified with mutation specific primer (ASO). 
Analysis of Mutation T1052C 
 
This mutation also confers Gleevec resistance in CML patients. 
For checking this thymine to cytosine substitution at position 
1052 of ABL gene in Gleevec-resistance CML patient, ASO-PCR 
was performed using mutation specific primer (Allele -specific 
oligonucleotide) as well as normal primer to give a PCR product 
of 112 bp. Although gel electrophoresis showed specific 
amplification both for patient and healthy control, 112 bp ASO -
PCR product was observed only for patient (Fig. 3). It is inferred 
that mutation C1052T mutation is also involved in this patient in 
conferring Gleevec resistance. 
 
Fig. 3: Detection of Mutation T1052C by ASO-PCR. Lane 1: Patient’s DNA 
amplified with normal primer, Lane 2: Patient’s DNA amplified with mutation 
specific primer (ASO), Lane 3: Control DNA amplified with normal primer, Lane 
4: Control DNA amplified with mutation specific primer (ASO), Lane 5: Negative 
control, Lane 6: DNA ladder (100 bp) Fermentas). 
 
On the basis of our results, we conclude that two mutations are 
responsible for primary Gleevec resistance in the CML patient 
under study. We also conclude that this ASO-PCR is very 
effective and sensitive to detect point mutations conferring 




CML is a very fatal disease which is very difficult to treat (23). 
Patients usually resist the chemotherapy like hydroxyurea and 
interferon-á (24). In recent years, Gleevec has fascinated the 
physicians, clinicians, patients and researchers by its high 
effectiveness against BCRABL positive CML patients (25). As it 
stops the oncogenic activity of bcr-abl onco-protein by binding 
to its ATP-binding site in kinase domain, it has fewer side effects 
than interferon and is thus well-tolerated (26). It binds to some 
amino acids in ATP -binding domain by making hydrogen bonds 
(12). Recently it was found that some mutations in ABL gene 
ATP–binding domain lead to conformational changes in bcr-abl 
oncoprotein, thus resulting in impairment of Gleevec binding and 
leading to clinical resistance (27). Some mutations cause complete 
Gleevec resistance as they completely stop the Gleevec binding 
to its target while other mutations only affect this binding 
partially, leading to only moderate resistance to this drug (14, 18, 
28). Thus, detection of mutations associated with Gleevec 
resistance is of a considerable clinical impact. 
 
Allele specific oligonucleotide (ASO) PCR is a very specific and Iqbal et al.    
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sensitive technique for detection of known mutations (29). This 
method is even sensitive than mutation detection by sequencing 
of ABL ATP-binding domain (30) because DNA sequencing can 
only useful for point mutation detection when proportion of 
mutated cells is more than 30% (21). In cases where number of 
mutated cells is less than 30% of the total cells in patient’s 
sample, at least 10 independent clones from the patient must be 
analysed for mutation detection which is quite costly and time 
consuming (21). On the other hand, ASO-PCR is comparatively 
more sensitive, specific, very economical and quick method for 
detection of mutations (31). The ASO-PCR established by us is 
able to detect one mutated, Gleevec resistant cell out of 10,000 
normal cells (21).  
 
In present study, we found two mutations in a Gleevec-resistant 
CML patient by ASO-PCR method. It is the first report of 
multiple mutations in a Gleevec resistant CML patient. A 
Thymine to cytosine mutation at position 1052 of ABL gene was 
detected. This mutation leads to amino acid substitution from 
Methionine to Threonine at position 351 of ABL ATP binding 
domain (18). This mutation only partially impairs the binding of 
Gleevec to its target and thus leads to partial drug resistance (21). 
This mutation has previously been reported (18). It has been 
authoritatively documented that partial Gleevec resistance can be 
actively overcome by dose escalation of Gleevec from 600-
1600mg/day (32). On the other hand, a cytosine to thymine 
mutation at ABL gene position 944 was detected which causes 
threonine to isoleucine amino acid substitution at amino acid 
position 315 in ATP-binding domain of bcr-abl oncoprotein. 
This mutation has already been reported by various authors like 
(12-14, 18, 33). It has been determined on the basis of crystal 
structure of abl kinase domain that Threonine 315 is among 
those amino acids which make hydrogen bonds with Gleevec by 
providing an oxygen atom (12). When isoleucine takes the place 
of threonine as a result of C944T mutation, it does not provide 
oxygen atom for binding (12). Moreover, it contains an extra 
hydrocarbon group in side chain which results in steric hindrance 
to Gleevec (12). Thus, binding of drug is completely impaired 
leading to complete drug resistance (18, 33). Complete Gleevec 
resistance can be managed clinical by combination therapies (34). 
Gleevec plus arsenic oxide, Gleevec plus Pegylated interferon-á 
and Gleevec plus Cytarabine have promising results for CML 
patients who show complete resistance to Gleevec (20, 35, 36). 
Moreover some new drugs like Farnesyl transferase inhibitors, 
Raf kinase inhibitors etc. which stop cancer pathway signaling by 
bcr-abl oncoprotein have been are under clinical trials with 
promising initial results (37). Another drug called Genasense 
which degrades BCR-ABL mRNA has promising results against 
Gleevec-resistant CML cases (38). Thus it is inferred in present 
situation that mutation detection related to Gleevec resistance 
has a great clinical importance. Gleevec resistance can be 
detected very early in one to three months after initiation of 
therapy (21) and molecular typing of Gleevec resistant patients 
on the basis of nature and location of mutations in ATP-binding 
domain can help in adjustment of therapy accordingly (18, 21, 35, 
39). 
 
It should be kept in mind that impact of mutations on Gleevec 
resistance reported so far is based on a single mutation for each 
patient. As this is first report of double mutation conferring 
Gleevec resistance in same patient and each mutation has 
different impact on drug resistance, biological significance of two 
or more ABL ATP-binding domain mutations conferring 
Gleevec resistance in same patient with a difference in resistance 
mechanism is still to be determined. It is, however, expected that 
such multiple mutations could result in much complicated 
Gleevec resistance patterns which might be found more difficult 
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